About this Research Topic
This Research Topic is apart of the series "The Future of Checkpoint Immunotherapy: New Roads Ahead". Please see the series here.
"Checkpoint Immunotherapy: Reshaping the Landscape of Gastrointestinal Cancer Treatment" is a comprehensive Research Topic that delves into the transformative impact of immunotherapy on the management of gastrointestinal malignancies.
Gastrointestinal cancers, encompassing tumors of the esophagus, stomach, liver, pancreas, colon, and rectum, pose significant challenges to patients and clinicians alike due to their complex nature and often limited treatment options. However, in recent years, the advent of checkpoint immunotherapy has revolutionized the field, offering new hope and avenues for improved outcomes.
We encourage researchers to submit original studies, reviews, and case reports that provide insights into the translational aspects of checkpoint immunotherapy in gastrointestinal cancers. This includes investigations into predictive biomarkers, mechanistic studies elucidating the tumor-immune microenvironment interactions, and preclinical models evaluating novel immunotherapeutic agents. Furthermore, this collection explores the complexities of patient selection and biomarker identification for optimal immunotherapy response. We examine the role of predictive biomarkers such as PD-L1 expression, tumor mutational burden, and microsatellite instability in guiding treatment decisions and enhancing patient outcomes.
We warmly welcome submissions of translational research that bridge the gap between scientific discoveries and clinical applications. Translational research plays a pivotal role in advancing our understanding of the underlying mechanisms of immunotherapy and its implications for gastrointestinal cancer treatment. By showcasing translational research, our collection aims to facilitate the translation of scientific insights into actionable strategies that can improve patient outcomes in clinical practice. We believe that fostering collaboration between basic scientists, translational researchers, and clinicians is essential for accelerating the development and implementation of effective immunotherapy approaches for gastrointestinal cancer patients.
This collection brings together leading experts and researchers in the field of oncology to explore the latest advancements, challenges, and future directions of checkpoint immunotherapy in gastrointestinal cancer treatment. Through a series of insightful articles, we aim to provide a comprehensive overview of the role of immunotherapy in reshaping the landscape of gastrointestinal cancer care.
The collection begins by examining the fundamentals of checkpoint immunotherapy, elucidating the underlying mechanisms of action and the rationale behind its application in gastrointestinal cancers. From there, we delve into the clinical efficacy of immunotherapy across different gastrointestinal cancer types, highlighting key trials, real-world evidence, and patient outcomes.
Authors are invited to contribute their innovative research findings and clinical experiences to "Checkpoint Immunotherapy: Reshaping the Landscape of Gastrointestinal Cancer Treatment" to advance the field and ultimately enhance the care of patients with gastrointestinal malignancies.
"Checkpoint Immunotherapy: Reshaping the Landscape of Gastrointestinal Cancer Treatment" is a comprehensive Research Topic that delves into the transformative impact of immunotherapy on the management of gastrointestinal malignancies.
Gastrointestinal cancers, encompassing tumors of the esophagus, stomach, liver, pancreas, colon, and rectum, pose significant challenges to patients and clinicians alike due to their complex nature and often limited treatment options. However, in recent years, the advent of checkpoint immunotherapy has revolutionized the field, offering new hope and avenues for improved outcomes.
We encourage researchers to submit original studies, reviews, and case reports that provide insights into the translational aspects of checkpoint immunotherapy in gastrointestinal cancers. This includes investigations into predictive biomarkers, mechanistic studies elucidating the tumor-immune microenvironment interactions, and preclinical models evaluating novel immunotherapeutic agents. Furthermore, this collection explores the complexities of patient selection and biomarker identification for optimal immunotherapy response. We examine the role of predictive biomarkers such as PD-L1 expression, tumor mutational burden, and microsatellite instability in guiding treatment decisions and enhancing patient outcomes.
We warmly welcome submissions of translational research that bridge the gap between scientific discoveries and clinical applications. Translational research plays a pivotal role in advancing our understanding of the underlying mechanisms of immunotherapy and its implications for gastrointestinal cancer treatment. By showcasing translational research, our collection aims to facilitate the translation of scientific insights into actionable strategies that can improve patient outcomes in clinical practice. We believe that fostering collaboration between basic scientists, translational researchers, and clinicians is essential for accelerating the development and implementation of effective immunotherapy approaches for gastrointestinal cancer patients.
This collection brings together leading experts and researchers in the field of oncology to explore the latest advancements, challenges, and future directions of checkpoint immunotherapy in gastrointestinal cancer treatment. Through a series of insightful articles, we aim to provide a comprehensive overview of the role of immunotherapy in reshaping the landscape of gastrointestinal cancer care.
The collection begins by examining the fundamentals of checkpoint immunotherapy, elucidating the underlying mechanisms of action and the rationale behind its application in gastrointestinal cancers. From there, we delve into the clinical efficacy of immunotherapy across different gastrointestinal cancer types, highlighting key trials, real-world evidence, and patient outcomes.
Authors are invited to contribute their innovative research findings and clinical experiences to "Checkpoint Immunotherapy: Reshaping the Landscape of Gastrointestinal Cancer Treatment" to advance the field and ultimately enhance the care of patients with gastrointestinal malignancies.
Keywords: Gastrointestinal cancer, Immunotherapy, Immune checkpoint inhibitors, Hepatocellular carcinoma, Colorectal cancer, Pancreatic cancer, Upper gastrointestinal cancer
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
